Vaxcyte, Inc.

Historical 13F Holders

Symbol
PCVX
CUSIP
92243G108
All holders as of
Q2 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 92243G108 since 12/18/2024, largest first.

Filer % of Class Filed
FMR LLC 13G/A
14.4% 8/6/2026
Event 6/30/2026
Janus Henderson Group Ltd. 13G/A 12.1% 8/11/2026
Event 7/31/2026
RA Capital Management, L.P. 13G/A
8.9% 5/15/2026
Event 3/31/2026
T. Rowe Price Investment Management, Inc. 13G/A 8.6% 2/17/2026
Event 12/31/2025
BlackRock, Inc. 13G/A 7.6% 4/17/2025
Event 3/31/2025
Vanguard Capital Management LLC 13G 5.0% 4/30/2026
Event 3/31/2026
Under 5%, checked the "5 percent or less" box, or amended by a later filing (1)
Vanguard Group Inc 13G/A 0% 3/27/2026
Event 3/13/2026

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q3 8 3.54 k $201 k
2026 Q2 359 176 M $9.87 B
2026 Q1 354 163 M $9.44 B
2025 Q4 311 154 M $7.12 B
2025 Q3 301 143 M $5.15 B
2025 Q2 313 151 M $4.92 B
2025 Q1 339 146 M $5.90 B
2024 Q4 351 141 M $11.5 B
2024 Q3 358 138 M $15.8 B
2024 Q2 286 124 M $9.40 B
2024 Q1 274 122 M $8.30 B
2023 Q4 239 105 M $6.59 B
2023 Q3 214 101 M $5.17 B
2023 Q2 214 100 M $5.00 B
2023 Q1 202 84.1 M $3.15 B
2022 Q4 222 84.8 M $4.07 B
2022 Q3 137 61.0 M $1.47 B
2022 Q2 110 51.4 M $1.12 B
2022 Q1 92 49.9 M $1.20 B
2021 Q4 92 44.7 M $1.06 B
2021 Q3 81 43.2 M $1.10 B
2021 Q2 77 43.2 M $973 M
2021 Q1 78 44.9 M $886 M
2020 Q4 84 42.3 M $1.12 B
2020 Q3 61 37.8 M $1.86 B
2020 Q2 40 36.0 M $1.13 B